In recent years the approach to heart failure has changed from one that focused on the haemodynamic changes at the basis of the syndrome or occurring as a result of it to one that recognises the significance of neuroendocrine activation not only for the occurrence of heart failure but also for its clinical expression and ultimate prognosis. Moreover, the fact that heart failure depends not only on cardiac changes but to a large extent on intrinsic peripheral changes has been gradually appreciated.
Consequently, the management of heart failure has taken a different turn, focusing now on modulation of neuroendocrine activation and other extracardiac abnormalities rather than trying to increase cardiac contractile force through positive inotropic treatment. This attitude has been reinforced by current doubts about the clinical efficacy and safety of positive inotropic treatment. As other physiologically more relevant treatments such as inhibition of angiotension converting enzyme have become available, it is not so much a question of when positive inotropic agents should be administered but whether there is in fact a place and need for this form of treatment.
In most patients, however, cardiac contractile dysfunction is the primary disorder and the origin of the heart failure, so intuitively, pharmacological interventions aimed at inotropic support have been considered important in treating heart failure for many years. Consequently, many inotropic agents have been developed. Positive inotropic drugs are categorised as cyclic AMP (cAMP) dependent or cAMP independent.
Whether they act through cAMP or not, inotropic drugs increase cardiac contractile force by altering the availability of calcium to the contractile proteins and by altering the interaction of calcium with the troponintropomyosin complex. In addition, cAMP dependent agents influence the velocity of contractile protein interaction and the sequestration of calcium from the cytosol after contraction.
cAMP formation depends on the activity of the adenylate cyclase system, which, in turn, depends on activation of stimulatory adrenergic versus inhibitory muscarinic or adenosine receptors and on the activity of stimulatory versus inhibitory regulating proteins, the G proteins (fig 1) . Once formed, cAMP is degraded to 5-AMP under the influence of soluble or membrane bound cGMP inhibited, cAMP specific phosphodiesterases of subtype III.
In the heart an increase of this second messenger leads to cAMP dependent phosphorylation of certain protein kinases, which affect the contraction-relaxation process in several ways. Firstly, the slow inward calcium current is increased through voltage dependent L type channels in the sarcolemma. This calcium is instrumental in the subsequent release of larger amounts of calcium from the sarcoplasmic reticulum into the cytosol at the contractile protein site. The degree of calcium induced calcium release determines the force of contraction.
Secondly, the concentration of cAMP is pivotal for myofibrillar ATPase activity and crossbridging cycling rate, and, hence, for contractility.
Finally, cAMP influences relaxation in various ways. Phosphorylation of phospholamban enhances calcium reuptake by the sarcoplasmic reticulum, whereas phosphorylation of troponin I reduces the calcium sensitivity of troponin C, both mechanisms enhancing cardiac relaxation.
cAMP INDEPENDENT MECHANISMS
There are several additional ways to interfere with cardiac contraction without affecting cAMP concentrations. Again, in these cAMP independent mechanisms calcium plays a central part. Experimental conditions which increase the intracellular calcium concentration directly or indirectly by introducing paired stimulation enhance contractile force in parallel with the change in inward calcium current.' For instance, cx adrenergic receptor stimulation increases inositol 1,4,5-triphosphate (IP3) concentrations, subsequently enhancing the inward calcium current and contractile force, whereas sarcolemmal calcium agonists may increase force by directly opening the calcium channels-for example, Bay K 8644.2 However, potentially more relevant mechanisms in terms of pharmacological modulation of intracellular calcium relate to either sarcolemmal sodium channel stimulation or to sarcolemmal sodiumpotassium ATPase inhibition (digitalis glycosides), the latter indirectly raising the concentration of intracellular calcium ions through increased sodium influx with subsequent sodium-calcium exchange.
A different approach towards increasing contractility is not to increase the Figure 1 Schematic representation of cardiac cyclic AMP (cAMP) formation and its interaction with contraction and relaxation. cAMP, formed after activation of the ,3 receptor(Rs) -Gs-adenylate cyclase axis, stimulates several protein kinases, subsequently enhancing sarcolemmal calcium fluxes, which release calcium from intracellular stores, such as the sarcoplasmatic reticulum. Binding of calcium with the troponin-tropomyosin complex (Ti, Tc, Tm, Tt) leads to actin-myosin interaction and contraction. Subsequent sequestration of cytosolic calcium into the sarcoplasmic reticulum and relaxation is enhanced by cAMP induced phosphorylation of protein kinases that affect the activity of phospholamban and Ti. cAMP is degraded to Moreover, the increase in Gia: may occur only in idiopathic cardiomyopathy. '6 Consequently, changes linked to the 1 adrenergic receptor in heart failure have important effects on cAMP formation in the heart. Deficient cAMP production undoubtedly is an important cause of contractile dysfunction in heart failure and of the lack of therapeutic efficacy of cAMP dependent positive inotropic support.
Moreover, the high adrenergic drive during heart failure which leads to these receptor changes also causes marked depletion of neurotransmitters in the heart. Both in idiopathic dilated cardiomyopathy and in ischaemic cardiomyopathy, tissue noradrenaline, adrenaline, dopamine, and neuropeptide Y concentrations are decreased. 9 Consequently, indirect acting 1 agonists, such as dopexamine and dopamine, lose their efficacy over time.
By contrast, cAMP independent inotropic mechanisms are possibly less affected by intrinsic cardiac changes. For instance, S 94 myocardial ot adrenergic receptor density is unchanged in heart failure. '7 18 Although this could be important because cx adrenergic stimulation elicits a positive inotropic response in humans, a diminished inotropic response has, nevertheless, been observed in heart failure, either as a result of receptor uncoupling or secondary to a general defect in the contractile potential in this condition.'9 By contrast, calcium sensitisation remains intact even in advanced stages of failure, and there is no evidence for a diminished efficacy of digitalis in advanced heart failure, at least not in in vitro experiments. Similarly, there are no data to indicate that sodium channel stimulation or other cAMP independent ways to increase intracellular calcium concentrations lose their inotropic efficacy in end stage heart failure.
Clinical efficacy of cAMP dependent inotropic agents SYMPATHOMIMETIC AGENTS (TABLE) Sympathomimetic agents are undoubtedly one of the cornerstones of the treatment of acute heart failure, particularly in low output conditions and in cardiogenic shock. Parenterally administered 13 and 12 adrenergic agents, dopamine, and, possibly, colforsin have clearly shown acute haemodynamic and clinical efficacy.
The effect is, however, comparatively short lived. Tolerance may occur after days, probably due to reduced 13 receptor responsiveness secondary to further receptor downregulation, an increase in Gin,s and possibly also inactivation of the adenylate cyclase system. Consequently, the capacity of the heart to produce cAMP diminishes. Although early studies suggested a sustained clinical improvement lasting for several weeks after a three day infusion of dobutamine, such improvement was observed only in a minority of patients and then specifically in those with a fairly well preserved function at baseline. Subsequent attempts to obviate long term In contrast, the partial P13 agonist and antagonist xamoterol has, for some time at least, been considered a useful addition to the therapeutic armamentarium in mild heart failure. Xamoterol probably does have a valuable role as an alternative to diuretics or in patients with heart failure and atrial fibrillation. It may have a special role in elderly patients with heart failure. Xamoterol may also be an excellent choice in patients with heart failure and angina. Indeed, amelioration of ischaemic left ventricular dysfunction rather than heart failure itself may be its principal mode of action. A controlled study in severe heart failure failed to show clinical improvement but showed that xamoterol increased mortality.24 Preliminary reports in patients with milder heart failure suggest a neutral or slightly favourable effect on survival.
DOPAMINERGIC AGENTS
In acute heart failure dopamine is extensively used in low output conditions to improve renal flow at lower doses and to improve cardiac output and blood pressure at higher doses. This reflects the pharmacological profile of the drug, which includes stimulation of dopaminergic 1 and 2 receptors and, at higher dosages, activation of 13, a,, and a2 receptors.
However, the major inotropic mechanism of action seems to be through cardiac adrenergic neurotransmittor release. with agents such as amrinone and enoximone significant improvements in exercise capacity or clinical wellbeing have not been sustained.34 3 One study that compared milrinone, digoxin, their combination, and placebo in patients with class III heart failure (New York Heart Association's classification) suggested an improvement with the PDE inhibitor.36 However, in this study, all patients were initially taking digoxin, which was withdrawn before randomisation. Although patients taking milrinone had better exercise capacity than the patients who received placebo, when they were compared with patients who continued to take digoxin there was no such effect. Rather than supporting the efficacy of milrinone, this study would favour the use of digoxin in moderate to severe heart failure. Figure 5 Biphasic pattern of constriction after ouabain has been added to coronary vascular strips. The first contraction is the direct effect of the drug and depends on available calcium. The second is absent in denervated strips and reduced after a blockade with prazosin, indicating noradrenaline release by digitalis.49 Reproduced with permission.
rather than an inotrope, and, consequently, the effects on mortality the result of an antiarrhythmic effect, is uncertain. Firstly, Feldman et al found that the reduction in mortality applied not only to patients dying suddenly but also to patients dying of progressive failure.46 Moreover, vesnarinone reduced the risk of worsening heart failure and improved quality of life. Secondly, available antiarrhythmic agents have thus far not appreciably affected mortality in progressive heart failure. The reasons for the unexpected beneficial effect of vesnarinone on survival and heart failure status are not clear, but they may include the combination of cAMP independent inotropic effects, antiarrhythmic properties, a bradycardiac effect, and, possibly, an inhibiting action on cytokine production. 48 There is some concern, though. Vesnarinone induces agranulocytosis in 2-5% of patients. Moreover, as will be discussed below, it probably has a narrow therapeutic range, like digitalis.46 DIGITALIS 
GLYCOSIDES
Digitalis glycosides inhibit the activity of membrane sodium-potassium ATPase. This results in raised intracellular sodium, which is exchanged for calcium through the sodiumcalcium exchanger. In addition, the rise in intracellular calcium concentration leads to an increase in hydrogen ions, which are exchanged for sodium, in turn leading to more intracellular calcium. This results in enhanced cardiac contractility and vasoconstriction.
In vitro, the vasocontrictor effects of digitalis are biphasic.49 Firstly, there is a contraction which depends on available calcium and reflects the direct constrictor effect of the drug. This is followed by a second vasoconstriction, which is lost in denervated vascular strips and reduced by coadministration of the ot, blocker prazosin, In subjects with normal cardiac function digitalis has a vasoconstrictor effect, although this depends on dose and rate of administration. Intravenous administration of ouabain for 10 seconds or two minutes causes a significant increase in systemic vascular resistance but not when a slower infusion rate is applied.5' In subjects without heart failure an intravenous bolus administration of digoxin results in coronary vasoconstriction with a significant reduction in the cross sectional area of both normal segments and arteries with coronary artery disease. 52 In heart failure the acute vasoconstrictor action of digitalis is counteracted by the modulating effects of digitalis on neurohormonal activation and by its sympathoinhibitory activity. Thus, in patients with heart failure digitalis may induce vasodilatation through direct or indirect attenuation of neuroendocrine activation. In addition to earlier observations by Mason and Braunwald of the peripheral vasodilating effects of ouabain in patients with heart failure and of vasoconstriction in normal subjects,50
Ferguson et al recently showed that short term treatment with digitalis reduces sympathetic nerve activity, resulting in systemic vasodilatation in patients with heart failure but not in normal subjects.53 Glycosides increase baroreceptor sensitivity, both in normal subjects and in patients with heart failure. Underlying mechanisms may include direct receptor stimulation, an effect related to inhibition of sodium-potassium ATPase, or a secondary response to improved haemodynamics. Several included only patients in whom digitalis could be withdrawn, hence introducing bias. Enrolment criteria often were not well defined-for example, the presence of systolic dysfunction and background treatment were not controlled for or specified and sample size was often inadequate.
A few studies have indicated that the addition of digitalis to existing treatment or its withdrawal under controlled conditions leads to clinical improvement or deterioration, respectively.65-67 Patients with heart failure and sinus rhythm who improved tended to be those with systolic dysfunction, large hearts, an S3 gallop, and heart failure (New York Heart Association class III) despite treatment. By contrast, the Dutch ibopamine multicentre trial suggested that digoxin exerted clinical benefits even in patients with moderate heart failure who were treated only with diuretics. 55 Two recent studies in patients with mild to moderate heart failure and sinus rhythm indicate that such patients also tend to deteriorate after abrupt withdrawal of digitalis.68 69 The RADIANCE study is particularly noteworthy in this respect, as all patients in this study, in contrast to previous investigations with digitalis, were taking ACE inhibitors69 (fig 6) . Thus, when clinical efficacy is concerned, it makes sense to give digitalis to patients with comparatively severe heart failure and sinus rhythm despite the accepted standard treatment of diuretics and ACE inhibitors. Also, it makes sense to continue digitalis when such patients have improved to a milder stage of heart failure. But how safe is digoxin?
What if digoxin increases mortality? Despite centuries of use, doctors do not know whether digitalis has an effect on mortality and whether this is favourable. Arrhythmias are a well recognised manifestation of digitalis toxicity. The therapeutic-toxic dose range is quite narrow under normal conditions; aging, abnormal renal haemodynamics, and the propensity for hypokalemia in heart failure may clearly enhance the potential for toxicity. Weeks after randomisation Figure 6 Worsening of exercise capacity in patients with mild heart failure previously taking digoxin, diuretics, and ACE inhibitors in whom digoxin was replaced by placebo. The comparison group continued to take digoxin.69
Reproduced with permission. 
